ANVS News

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

Annovis Appoints Mark Guerin as Chief Financial Officer